Wei Shen Tan

Dr. Wei Shen Tan

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

31 January 2017 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
AFAndrew Feber
Andrew Feber
PDPawan Dhami
Pawan Dhami
LDLiqin Dong
Liqin Dong
PWPatricia de Winter
Patricia de Winter
WTWei Shen Tan
Wei Shen Tan
JKJohn D. Kelly
John D. Kelly
Bladder cancer (BC) is one of the most common cancers in the western world and ranks as the most expensive to manage, due to the need for cystoscopic examination. BC shows frequent changes in DNA methylation, and several studies have shown the potential utility of urinary biomarkers by detecting epigenetic alterations in voided urine. The aim of this study is to develop a targeted bisulfite next-generation sequencing assay to diagnose BC from urine with high sensitivity and specificity. We defined a 150 CpG loci biomarker panel from a cohort of 86 muscle-invasive bladder cancers and 30 normal urothelium. Based on this panel, we developed the UroMark assay, a next-generation bisulphite sequencing assay and analysis pipeline for the detection of bladder cancer from urinary sediment DNA. The 150 loci UroMark assay was validated in an independent cohort (n = 274, non-cancer (n = 167) and bladder cancer (n = 107)) voided urine samples with an AUC of 97%. The UroMark classifier sensitivity of 98%, specificity of 97% and NPV of 97% for the detection of primary BC was compared to non-BC urine. Epigenetic urinary biomarkers for detection of BC have the potential to revolutionise the management of this disease. In this proof of concept study, we show the development and utility of a novel high-throughput, next-generation sequencing-based biomarker for the detection of BC-specific epigenetic alterations in urine.

1 June 2016 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
WTWei Shen Tan
Wei Shen Tan
SRSimon Rodney
Simon Rodney
BLBenjamin Lamb
Benjamin Lamb
MFMark Feneley
Mark Feneley
JKJohn Kelly
John Kelly

1 July 2018 in European Urology
Verified
Journal Article
Closed access
WTWei Shen Tan
Wei Shen Tan
AFAndrew Feber
Andrew Feber
RSRachael Sarpong
Rachael Sarpong
PKPramit Khetrapal
Pramit Khetrapal
SRSimon Rodney
Simon Rodney
JKJohn D. Kelly
John D. Kelly

1 September 2018 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
WTWei Shen Tan
Wei Shen Tan
WTWei Phin Tan
Wei Phin Tan
MTMae-Yen Tan
Mae-Yen Tan
PKPramit Khetrapal
Pramit Khetrapal
LDLiqin Dong
Liqin Dong
JKJohn D. Kelly
John D. Kelly

1 November 2018 in Journal of Urology
Verified
Journal Article
Open access
WTWei Shen Tan
Wei Shen Tan
RSRachael Sarpong
Rachael Sarpong
PKPramit Khetrapal
Pramit Khetrapal
SRSimon Rodney
Simon Rodney
HMHugh Mostafid
Hugh Mostafid
DCDetect I Trial Collaborators
Detect I Trial Collaborators
Computerized tomography urogram is recommended when investigating patients with hematuria. We determined the incidence of urinary tract cancer and compared the diagnostic accuracy of computerized tomography urogram to that of renal and bladder ultrasound for identifying urinary tract cancer. The DETECT (Detecting Bladder Cancer Using the UroMark Test) I study is a prospective observational study recruiting patients 18 years old or older following presentation with macroscopic or microscopic hematuria at a total of 40 hospitals. All patients underwent cystoscopy and upper tract imaging comprising computerized tomography urogram and/or renal and bladder ultrasound. A total of 3,556 patients with a median age of 68 years were recruited in this study, of whom 2,166 underwent renal and bladder ultrasound, and 1,692 underwent computerized tomography urogram in addition to cystoscopy. The incidence of bladder, renal and upper tract urothelial cancer was 11.0%, 1.4% and 0.8%, respectively, in macroscopic hematuria cases. Patients with microscopic hematuria had a 2.7%, 0.4% and 0% incidence of bladder, renal and upper tract urothelial cancer, respectively. The sensitivity and negative predictive value of renal and bladder ultrasound to detect renal cancer were 85.7% and 99.9% but they were 14.3% and 99.7%, respectively, to detect upper tract urothelial cancer. Renal and bladder ultrasound was poor at identifying renal calculi. Renal and bladder ultrasound sensitivity was lower than that of computerized tomography urogram to detect bladder cancer (each less than 85%). Cystoscopy had 98.3% specificity and 83.9% positive predictive value. Computerized tomography urogram can be safely replaced by renal and bladder ultrasound in patients who have microscopic hematuria. The incidence of upper tract urothelial cancer is 0.8% in patients with macroscopic hematuria and computerized tomography urogram is recommended. Patients with suspected renal calculi require noncontrast renal tract computerized tomography. Imaging cannot replace cystoscopy to diagnose bladder cancer.